Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Imafuku, Shinichi
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis	Recruiting	3	1300	Europe, Canada, Japan, US, RoW	TAK-279	Takeda	Plaque Psoriasis	05/26	05/26
LATITUDE-PsA-3002, NCT06671496: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines	Recruiting	3	600	Europe, Canada, Japan, US, RoW	Zasocitinib, TAK- 279, NDI-034858, Placebo	Takeda	Psoriatic Arthritis	05/27	01/28
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment	Active, not recruiting	3	693	Europe, Canada, Japan, US, RoW	TAK-279, Placebo, Apremilast	Takeda	Plaque Psoriasis	08/25	04/26
Irie, Makoto
No trials found
Kawasaki, Hiroaki
No trials found
Shakado, Satoshi
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Imafuku, Shinichi
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis	Recruiting	3	1300	Europe, Canada, Japan, US, RoW	TAK-279	Takeda	Plaque Psoriasis	05/26	05/26
LATITUDE-PsA-3002, NCT06671496: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines	Recruiting	3	600	Europe, Canada, Japan, US, RoW	Zasocitinib, TAK- 279, NDI-034858, Placebo	Takeda	Psoriatic Arthritis	05/27	01/28
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment	Active, not recruiting	3	693	Europe, Canada, Japan, US, RoW	TAK-279, Placebo, Apremilast	Takeda	Plaque Psoriasis	08/25	04/26
Irie, Makoto
No trials found
Kawasaki, Hiroaki
No trials found
Shakado, Satoshi
No trials found